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The Hippo pathway is crucial in organ size control,
and its dysregulation contributes to tumorigenesis.
However, upstream signals that regulate the mam-
malian Hippo pathway have remained elusive. Here,
we report that the Hippo pathway is regulated by
G-protein-coupled receptor (GPCR) signaling.
Serum-borne lysophosphatidic acid (LPA) and sphin-
gosine 1-phosphophate (S1P) act through G12/13-
coupled receptors to inhibit the Hippo pathway
kinases Lats1/2, thereby activating YAP and TAZ
transcription coactivators, which are oncoproteins
repressed by Lats1/2. YAP and TAZ are involved in
LPA-induced gene expression, cell migration, and
proliferation. In contrast, stimulation of Gs-coupled
receptors by glucagon or epinephrine activates
Lats1/2 kinase activity, thereby inhibiting YAP func-
tion. Thus, GPCR signaling can either activate or
inhibit the Hippo-YAP pathway depending on the
coupled G protein. Our study identifies extracellular
diffusible signals that modulate the Hippo pathway
and also establishes the Hippo-YAP pathway as a
critical signaling branch downstream of GPCR.INTRODUCTION
How organ size is controlled in multicellular organisms remains
a fundamental biological question. The mammalian target of
rapamycin (mTOR) pathway and the Hippo pathway have been
proposed to control organ size by affecting cell size and cell
number, respectively (reviewed in Lee et al., 2007; Zhao et al.,
2010a). The Hippo pathway was initially defined by genetic
studies in Drosophila, wherein mosaic mutations of Hippo
pathway genes resulted in tissue overgrowth (reviewed in Pan,
2007). Genetically modified mouse models demonstrate that780 Cell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc.function of the Hippo pathway in organ size regulation is
conserved in mammals (reviewed in Zhao et al., 2010a).
The kinase cascade of MST1/2 and Lats1/2 represents a core
component of the mammalian Hippo pathway. MST1/2, in
complexwith a regulatory protein salvador (Sav1), phosphorylate
and activate Lats1/2 kinases, which also form a complex with
a regulatory protein Mob1 (Zhao et al., 2010a). The transcription
coactivator Yes-associated protein (YAP) is amajor downstream
effector of the Hippo pathway (Dong et al., 2007). Lats1/2 inhibit
YAP by direct phosphorylation at S127, which results in YAP
binding to 14-3-3 and cytoplasmic sequestration (Dong et al.,
2007;Haoet al., 2008; Zhaoet al., 2007). YAPactsmainly through
TEAD family transcription factors to stimulate expression of
genes that promote proliferation and inhibit apoptosis (Zhao
et al., 2008). Phosphorylation of YAP S381 by Lats1/2 kinases
can also promote its ubiquitination-dependent degradation
(Zhao et al., 2010b). TAZ is a YAP paralog in mammals similarly
regulated by the Hippo pathway (Lei et al., 2008).
In transgenic mice, YAP promotes liver enlargement in a
reversible manner (Camargo et al., 2007; Dong et al., 2007), sug-
gesting that organ size control relies on tight regulation of Hippo
pathway activity. Sustained YAP expression results in hyper-
plasia and eventual tumor development (Dong et al., 2007).
Genetic ablation of Hippo pathway components in mice also
leads to tumor formation (Benhamouche et al., 2010; Cai et al.,
2010; Lee et al., 2010; Lu et al., 2010; Xu et al., 2009; Zhang
et al., 2010; Zhou et al., 2009). Moreover, abnormal activation
of YAP and TAZ has been associated with human cancers (Over-
holtzer et al., 2006; Steinhardt et al., 2008; Zender et al., 2006;
Zhao et al., 2007), suggesting an important role for the Hippo
pathway in tumorigenesis.
Despite extensive studies that have identified many upstream
components of the Hippo pathway, extracellular ligands and cell
surface receptors regulating the Hippo pathway have remained
elusive. Although CD44 has been proposed to impact the Hippo
pathway (Xu et al., 2010), further studies are required to demon-
strate the physiological relevance of CD44 in Hippo pathway
regulation. In this study, we report the identification of various
GPCRs and their agonists as Hippo pathway regulators.
Figure 1. Serum Induces Dephosphorylation of YAP and TAZ
(A and B) Serum induces YAP and TAZ dephosphorylation. HEK293A cells
were starved in serum-free medium for 12 hr and then stimulated with 10%
FBS for the indicated times (A) or with different concentrations of FBS for 1 hr
(B). Cell lysates were subjected to immunoblotting with the indicated anti-
bodies. Where indicated, gels containing phos-tag were employed for
assessment of YAP phosphorylation status (A, bottom). l.e., long exposure.
(C) Serum reversibly regulates YAP/TAZ phosphorylation. Serum-starved
HEK293A cells were treated with 10% FBS for 1 or 2 hr as indicated. In the last
three lanes, after 1 hr stimulation, FBS was removed for 1/4, 1/2, or 1 hr as
indicated by upward arrows.
(D) Serum induces YAP nuclear localization in HEK293A and MCF10A cells.
YAP subcellular localization was determined by immunofluorescence staining
for endogenous YAP (green) along with DAPI for DNA (blue). Serum stimulation
(10% FBS for 1 hr) is indicated.
Data are representative of at least three independent experiments. See also
Figure S1.Activation of Gs-coupled receptors by epinephrine or glucagon
stimulation increases Lats1/2 kinase activity, thus resulting in
inhibition of YAP function. In contrast, activation of G12/13- or
Gq/11-coupled receptors by lysophosphatidic acid (LPA) or
sphingosine 1-phosphate (S1P) inhibits Lats1/2 kinases, result-
ing in YAP activation. Our study demonstrates an important
role for the Hippo-YAP pathway in mediating the physiological
functions of GPCRs and their corresponding extracellular
ligands.
RESULTS
Serum Induces Dephosphorylation and Nuclear
Localization of YAP
In search of signals that might regulate YAP phosphorylation, we
found that, in HEK293A cells, YAP was highly phosphorylated
following serum starvation, and addition of serum resulted in a
rapid decrease in YAP phosphorylation as determined by immu-
noblotting using a phospho-YAP antibody (S127) and differential
migration on phos-tag-containing gels (Figure 1A). This phenom-
enon was observed in multiple cell lines, including HeLa, RC3,
SK-Mel-28, SF268, U2OS, and MCF10A (Figures S1A–S1D
available online). The effect of serum on YAP phosphorylation
was transient, as YAP phosphorylation was partially recovered
4 hr after serum stimulation (Figure 1A). Serum also caused a
mobility shift of TAZ, suggesting that TAZ was also dephos-
phorylated in response to serum (Figure 1A). Along with
decreased phosphorylation, protein levels of both YAP and
TAZ, especially TAZ, were increased by serum, consistent with
previous observations that phosphorylation promotes YAP/
TAZ degradation (Liu et al., 2010; Zhao et al., 2010b). In contrast,
protein levels of the MST1 and Lats1 were unaffected by serum
stimulation (Figure 1A).
The effect of serum on YAP/TAZ phosphorylation was dose
dependent. YAP dephosphorylation was evident when as
little as 0.5% serum was added (Figure 1B). Moreover, serum-
induced YAP dephosphorylation was rapid (visible at 5 min;
Figure S1B) and reversible (Figure 1C), indicating that the effect
of serum on YAP phosphorylation is likely a direct signaling
event. Phosphorylation of YAP at S127 leads to YAP cytoplasmic
localization (Zhao et al., 2007). Consistently, serum caused
a significant nuclear accumulation of YAP in both HEK293A
and MCF10A cells (Figure 1D). These data demonstrate that a
component in serum could potently activate YAP by inducing
dephosphorylation and nuclear localization.
Identification of LPA as a YAP-Activating Component
in Serum
To rule out the possibility that the YAP/TAZ activating compo-
nent(s) was present in a particular batch of serum, we examined
serum from different sources and found that all could induce
YAP dephosphorylation (Figure 2A). In contrast, a defined
embryonic stem cell culture medium (mTeSR1) that contains
several growth factors showed no effect on YAP phosphoryla-
tion, although phosphorylation of extracellular-signal-regulated
kinases (ERKs) was induced (Figure 2A), suggesting that growth
factors present in mTesR1 do not regulate YAP phosphorylation.
Moreover, we tested several growth factors, including insulin,Cell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc. 781
Figure 2. Characterization of Serum
Factor(s) Responsible for YAP/TAZ
Dephosphorylation
(A) Serum contains a YAP-activating activity.
HEK293A cells were treated with 10% of different
brands of serum: FBS (from Omega Scientific or
Hyclone [HC]), fetal calf serum (FCS), horse serum
(HS), or 10% mTesr1. Total cell lysates were
subjected to immunoblotting.
(B) The YAP-activating activity in serum is pro-
tease resistant. FBS were pretreated with pronase
E or heat-inactivated pronase E (HI). The effec-
tiveness of pronase E was demonstrated by
Coomassie blue staining (left). Cells were stimu-
lated with control or pronase-E-treated FBS.
(C) YAP-activating activity in BSA. Different BSA
preparations (from Sigma Aldrich) were used to
treat HEK293A cells. A3294 was prepared by heat
shock; A7073 fraction V (FV) and A6003 (fatty acid
[FA]-free) were prepared by ethanol precipitation;
and A2058 was prepared by chromatography.
Protein contents of different BSA preparations
were similar, as indicated by Coomassie blue
staining (data not shown). Serum-starved
HEK293A cells were treated with 1 or 10 mg/ml
BSA for 1 hr before harvest.
(D) Charcoal treatment depletes the YAP-acti-
vating activity in serum. 10% or 1% of regular or
charcoal-stripped (Ch) FBS was used to stimulate
serum-starved HEK293A cells for 1 hr.
(E) The YAP-activating activity in FBS is sensitive
to organic extraction under acidic conditions. FBS
was extracted using chloroform, methanol, or
different ratios of chloroform and methanol
mixture (CM, in the presence of HCl or NaOH).
Organic solvent was evaporated, and materials
extracted were dissolved in 2mg/ml fatty acid-free
BSA (FAF) and used to treat cells.
(F) LPA induces YAP dephosphorylation.
HEK293A cells were treated with 100 mM of
various lipids. Full names of lipids used are shown
in Extended Experimental Procedures.
Data are representative of at least three indepen-
dent experiments. Also see Figure S2.EGF, FGF, and PDGF, and found that their evoked signaling
pathways were not involved in YAP/TAZ activation (Figures
S1E and S1F), indicating that the active component(s) commonly
present in serum is unlikely a general growth factor. Further, inhi-
bition of MEK by U0126, PI3K by wortmannin, mTOR by torin,
and p38 by SB253580 had no effect on the ability of FBS to
induce dephosphorylation of YAP/TAZ (Figures S1G and S1H).
In order to determine whether a protein component in serum
is responsible for YAP/TAZ activation, we treated serum with
pronase E, which effectively degraded serum proteins (Fig-
ure 2B). Interestingly, we found that the activity in serum that
induces YAP/TAZ dephosphorylation was largely unaffected
by pronase treatment (Figure 2B). Moreover, the YAP/TAZ-de-
phosphorylating activity was resistant to heating and dialysis
(data not shown). These observations indicate that the YAP/
TAZ-activating factor(s) in serum is not a protein but is likely
a macromolecule or a small molecule tightly associated with a
macromolecule.782 Cell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc.Bovine serum albumin (BSA) was included as a control in our
studies. Surprisingly, BSA also potently decreased YAP/TAZ
phosphorylation (Figure 2C). BSA is a major serum component
that functions as a carrier for many molecules. We therefore
tested different BSA preparations on YAP/TAZ phosphorylation.
Whereas some BSA preparations induced YAP/TAZ dephos-
phorylation, fatty acid-free BSA and fraction V BSA displayed
no activity toward YAP/TAZ phosphorylation (Figure 2C). Similar
to fatty acid-free BSA, fraction V BSA contains fewer lipids
because it is prepared by ethanol precipitation. These observa-
tions suggest that a hydrophobic compound in BSA, possibly
a lipid, is responsible for inducing YAP/TAZ dephosphorylation.
In support of this hypothesis, charcoal-stripped FBS, which
has reduced lipid content, had a markedly decreased ability to
induce YAP dephosphorylation (Figure 2D).
To further characterize the YAP/TAZ-dephosphorylating
activity in FBS, we performed a series of extraction experiments
using different organic solvents (Quehenberger et al., 2010).
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Figure 3. LPA and S1P Activate YAP/TAZ by Dephosphorylation
(A) HEK293A cells were treated with 1 mM LPA for the indicated times. Cell
lysates were subjected to immunoblotting with the indicated antibodies.
(B) Serum and LPA stimulate YAP interaction with TEAD1 but inhibit YAP
interaction with 14-3-3. Cells were treated with LPA or serum as indicated.
Cell lysateswere subjected to immunoprecipitation (IP) with control IgG or YAP
antibody. The co-immunoprecipitated TEAD1 and 14-3-3 were detected by
immunoblotting.
(C) LPA treatment (1 mM for 1 hr) induces YAP nuclear localization in HEK293A
and MCF10A cells.
(D) HEK293A cells were treated with 1 mM S1P for the indicated times.
Data are representative of at least three independent experiments. Also see
Figures S2 and S3.Chloroform failed to extract the activity, whereas methanol or
ethanol could extract the activity (Figure 2E and data not shown).
Moreover, a chloroform/methanol mixture effectively extracted
the activity only at low pH, but not at high pH (Figure 2E). These
results suggest that the active ingredient in serum is an amphi-philic molecule with an acidic group. At low pH, the acidic group
in the active component is not charged, allowing it to be ex-
tracted by chloroform/methanol. In contrast, at high pH, the
acidic group in the active component is charged and thus could
not partition into the organic solvents. Phospholipids, particu-
larly lysophospholipids, which have hydrophobic tails with
phosphate heads, represent the best known examples of
amphiphilic-signaling molecules. Thus, we tested whether phos-
pholipids might induce YAP dephosphorylation. Among the
phospholipids tested, we found that phosphatidic acid (PA),
LPA, and a mixture of PA and phosphoinositol strongly induced
dephosphorylation of YAP/TAZ (Figure 2F).
LPA and S1P Stimulate YAP/TAZ Activity
LPA is a family of glycerophospholipid-signaling molecules
present in all tissues and serum (Choi et al., 2010). Low concen-
trations of LPA were effective in inducing YAP/TAZ dephosphor-
ylation, with 0.01 mM and 0.1 mM inducing partial and complete
YAP/TAZ dephosphorylation, respectively (Figure S2A), indi-
cating that LPA could activate YAP/TAZ at physiological (submi-
cromolar) concentrations (Choi et al., 2010). Next, we examined
various LPA isoforms with different lengths and degrees of satu-
ration of the fatty acid tails and found that all tested isoforms
could induce YAP/TAZ dephosphorylation (Figure S2B). We
subsequently tested PA and found that a much higher concen-
tration, 100 mM, was needed to induce YAP dephosphorylation
(Figure S2C). Because PA can be converted to LPA by phospho-
lipases and is significantly less potent than LPA, our data
suggest that PAmay not directly induce YAP dephosphorylation.
Rather, the conversion of PA to LPA or residual LPA contamina-
tion in the PA preparation might contribute to the activity de-
tected at high concentrations of PA (Figure 2F).
Similar to serum, LPA induced rapid YAP/TAZ dephosphoryla-
tion at S127 (Figure 3A). Lats can phosphorylate YAP on five
serine residues, including S381, with phosphorylation at S381
priming S384 phosphorylation by casein kinase (Zhao et al.,
2010b). Indeed, we found that phosphorylation of S381/384
was also decreased in response to LPA treatment (Figure S3A).
YAP S127 phosphorylation is required for 14-3-3 binding and
cytoplasmic retention. Consistent with its ability to promote
YAP dephosphorylation, LPA treatment attenuated YAP-14-3-3
interaction (Figure 3B) and induced YAP nuclear localization (Fig-
ure 3C). The subcellular localization of YAP was reversible, as
YAP protein redistributed into cytoplasm 30 min after LPA with-
drawal (Figure S3B). LPA also enhanced the interaction between
YAP and the nuclear-localized TEAD1, a transcription factor
target of YAP/TAZ (Figure 3B).
The S1P group of lysophospholipids has overlapping physio-
logical functions with LPA (Rosen et al., 2009). Similar to LPA,
S1P potently induced YAP/TAZ dephosphorylation (Figures 3D
and S2D). Taken together, our data demonstrate that LPA and
S1P are activators of YAP/TAZ.
YAP and TAZ Are Involved in LPA-Induced Gene
Expression, Cell Migration, and Cell Proliferation
As a transcription coactivator, the major function of YAP/TAZ is
to stimulate gene expression. CTGF, Cyr61, and ANKRD1 are
well-characterized YAP target genes. Indeed, LPA, S1P, andCell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc. 783
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Figure 4. YAP/TAZ Are Required for LPA
Functions and Are Regulated by LPA
Signaling
(A) YAP/TAZ are required for LPA to induce gene
expression. mRNA levels of the indicated genes
were measured by quantitative PCR. LPA (1 mM)
treatment was for 1 hr. HEK293A cells with stable
knockdown of YAP/TAZ or control cells were
used.
(B) Knockdown of YAP/TAZ blocks LPA-induced
cell migration. Migration of MCF10A cells trans-
fected with control siRNA or YAP/TAZ siRNA was
assessed by transwell cell migration assays.
(C) YAP/TAZ is required for LPA to stimulate cell
proliferation. Control and YAP/TAZ knockdown
HEK293A cells were cultured in the absence of
FBS and treatedwith or without 10 mMLPA for 0, 1,
2, or 3 days as indicated. LPA was replenished
every day. Cell number was then counted.
(D) Hyperplasia caused by transgenic LPA1 and
LPA2 expression. Hematoxylin and eosin staining.
(E) LPA receptor transgenic mouse tissues exhibit
increased TAZ nuclear localization. Immunofluo-
rescence staining for TAZ (red) and DNA (blue).
(F) LPA receptor transgenic mouse tissues exhibit
decreased YAP/TAZ phosphorylation. Sample in
each lane was from an individual mouse.
Mammary tissues were analyzed in (D–F).
Data are representative of at least three indepen-
dent experiments. Error bars represent SD; n = 3.
Also see Figure S4.serum treatment induced the expression of CTGF (Figures 1A,
3A, and 3B). Further mRNA and/or protein levels of CTGF,
Cyr61, and ANKRD1were also increased in cells stably express-
ing ectopic LPA receptor (LPA1) and autotaxin (ATX, an LPA-
producing enzyme; Figures S4A and S4B). To determine the
function of YAP/TAZ in LPA-induced gene expression, YAP
and TAZ were knocked down using shRNAs (Figure S4C). We
found that knockdown of YAP/TAZ strongly repressed the
mRNA induction of CTGF, Cyr61, ANKRD1, TAGLN, EDN1,
and PPP1R3B by LPA (Figure 4A), supporting a role of YAP/
TAZ in LPA-induced gene expression. However, the expression
of two other LPA-inducible genes, EGR3 and EGR4, was not
dependent on YAP/TAZ (Figure 4A). LPA is known to activate
multiple signaling pathways, including ERK (Figure 3A). Indeed,
both EGR3 and ERG4 are regulated by ERK activation (Li
et al., 2007; Ludwig et al., 2011).
LPA is known to stimulate cell migration and has been impli-
cated in tumor metastasis (Shida et al., 2003). We examined
the effect of YAP/TAZ knockdown in MCF10A cells (Figure S4D)
on cell migration using a transwell migration assay. We found784 Cell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc.that LPA-stimulated cell migration was
strongly inhibited in YAP/TAZ double-
knockdown cells (Figure 4B). In a
wound-healing assay, YAP/TAZ knock-
down also blocked the effect of LPA on
cell migration (Figure S4E). Another well-
characterized function of LPA is to
promote cell proliferation (van Corvenet al., 1989). We found that HEK293A cells displayed little
proliferation in the absence of serum, and addition of LPA
induced cell proliferation in control cells, but not in YAP/TAZ
double-knockdown cells (Figure 4C). These data demonstrate
important roles for YAP/TAZ in mediating physiological functions
of LPA.
It has been shown that TAZ expression is elevated in invasive
human breast cancers (Chan et al., 2008), and overexpression of
the LPA receptor in mousemammary glands causes hyperplasia
and tumor formation (Liu et al., 2009). To determine whether LPA
receptors regulate YAP/TAZ in vivo, we analyzed an LPA
receptor transgenic mouse model. As expected, LPA1 and
LPA2 transgenic mammary tissues exhibited massive over-
growth (Figure 4D). In contrast to the cytoplasmic localization
of TAZ in control tissues, TAZ was enriched in the cell nucleus
of LPA1 and LPA2 transgenic tissues (Figures 4E and S4F). Addi-
tionally, YAP/TAZ were dephosphorylated in LPA receptor trans-
genic mammary tissues and tumors (Figure 4F). Moreover, in
LPA2 tumors, the protein levels of YAP/TAZ and their target
gene, CTGF, were significantly upregulated (Figure S4G). The
Figure 5. LPA and S1P Repress Lats Kinase
Activity
(A) MST1/2 are not required for LPA-induced YAP
dephosphorylation and CTGF induction in MEF
cells. WT or knockout MEF cells at similar density
were untreated or treated with 1 mM LPA for 1 hr.
YAP phosphorylation was assessed by immuno-
blotting in the presence of phos-tag.
(B) Lats kinase activity is inhibited by LPA.
Endogenous Lats1 was immunoprecipitated
from HEK293A cells that had been treated with
LPA at various times and doses of LPA, and Lats1
kinase activity was determined using GTS-YAP as
a substrate.
(C) Lats phosphorylation is repressed by LPA. Cell
lysates from control or LPA-treated (1 mM for 1 hr)
cells were divided into two parts, one for IgG IP and
the other for Lats1 IP. Endogenous Lats1 was
immunoprecipitated and probed with phospho-
specific antibodies.
(D) Lats overexpression suppresses the effect of
LPA on YAP phosphorylation. HEK293A cells were
cotransfected with Flag-YAP and HA-Lats2 or HA-
Mob. At 1 day after transfection, cells were serum
starved for 24 hr and then treated with 1 mM LPA
for 1 hr.
Data are representative of at least three indepen-
dent experiments. Also see also Figure S5.above observations support a role of LPA signaling in promoting
YAP/TAZ dephosphorylation and activation in vivo.
LPA Inhibits Lats1/2 Kinase Activity
To determine whether LPA acts through the Hippo pathway core
components MST and Lats kinases to regulate YAP phosphory-
lation, we examined the effect of LPA on MST1/2 and Lats1/2
kinase activities. We found that LPA and serum had no detect-
able effect on MST1 kinase activity as visualized by in vitro
phosphorylation of Mob, a known MST1/2 substrate, and
MST1 autophosphorylation (Figure S5A). Similarly, the phos-
phorylation of MST2 at T180 was not changed following LPA
treatment (Figure S5B). In addition, LPA induced YAP dephos-
phorylation in MST1/2 double-knockout MEF cells (Figure 5A),
indicating that MST1/2 are not required for YAP regulation by
LPA in MEF cells.
Next, we measured Lats1 kinase activity and found that Lats1
kinase activity was rapidly inhibited by serum or LPA treatment
(Figures 5B and S5C). The inhibition of Lats1 kinase activity by
serum and LPA correlated with the repression of endogenous
YAP phosphorylation in both dose- and time-dependent
manners (Figure S5C), suggesting that LPA and serum decrease
YAP phosphorylation by inhibiting Lats1/2 kinase activity.
Consistent with the observed Lats inhibition, phosphorylation
levels of Lats1 at activation loop (S909) and hydrophobic motifCell 150, 780–79(T1079), both of which determine Lats
activity, were decreased upon LPA
treatment (Figure 5C). Moreover, the
effect of LPA on YAP phosphorylation
was abolished by overexpression of
Lats2 (Figure 5D), reinforcing the role ofLats1/2 inhibition in LPA-induced YAP activation. Our data
show that LPA signaling acts upstream of Lats1/2 and parallel
to MST1/2.
LPA/S1P Act through G12/13-Coupled Receptors
and Rho to Induce YAP/TAZ Dephosphorylation
LPA binds to a family of GPCRs known as LPA receptors
(LPA1–6) to initiate intracellular signaling (Choi et al., 2010).
LPA1 was highly expressed, and LPA3 was detectable in
HEK293A cells compared to other LPA receptors (Figure S6A).
To determine whether LPA receptors were required for LPA-
induced YAP/TAZ activation, we treated HEK293A cells with
Ki16425, which preferentially inhibits LPA1 and LPA3 (Ohta
et al., 2003). Ki16425 treatment blocked LPA-induced, but not
S1P-induced, dephosphorylation of YAP/TAZ (Figure 6A), sug-
gesting that LPA1 and LPA3mediate LPA-induced YAP dephos-
phorylation in HEK293A cells. Consistently, LPA-induced YAP
dephosphorylation was significantly blocked by stable knock-
down of LPA1 and LPA3 (Figure S6B). Furthermore, ectopic
expression of LPA and S1P receptors was sufficient to induce
YAP nuclear localization and dephosphorylation (Figures 6B
and S6C). These data suggest that the effect of LPA or S1P on
the Hippo-YAP pathway ismediated by their cognate transmem-
brane receptors. Of note, Ki16425 partially inhibited the ability of
serum to repress YAP/TAZ phosphorylation, particularly at low1, August 17, 2012 ª2012 Elsevier Inc. 785
Figure 6. LPA and S1P Modulate YAP/TAZ
through Their Membrane Receptors and
Rho GTPases
(A) LPA1/3 antagonist Ki16425 completely blocks
LPA and partially blocks serum effects on YAP/
TAZ phosphorylation. HEK293A cells were treated
with Ki16425 (10 mM) or DMSO control for 30 min
as indicated, and then cells were stimulated with
S1P, LPA, or FBS for 1 hr.
(B) LPA and S1P receptor overexpression pro-
motes YAP nuclear localization. Cells were trans-
fected with HA-tagged LPA1, LPA4, or S1P2 as
indicated. The transfected receptors were de-
tected by HA antibody (red), and endogenous YAP
was detected by YAP antibody (green). Note that
the receptor-expressing red cells have higher
nuclear YAP.
(C) Knockdown of G12 and G13 blocks the effect
of LPA on YAP phosphorylation. HEK293A cells
were transfected with control siRNA, a pool of
siRNAs for G12 and G13, or a pool of siRNAs for
Gq and G11; serum was removed at 48 hr.
Following 16 hr serum starvation, cells were
treated with 1 mM LPA for 1 hr.
(D) Inactivation of Rho by C3 toxin prevents YAP/
TAZ dephosphorylation by LPA, S1P, and serum.
HEK293A cells were pretreated with 2 mg/ml C3
for 4 hr and then stimulated with LPA, S1P, or FBS
for 1 hr.
(E) Disruption of actin cytoskeleton prevents YAP/
TAZ dephosphorylation by LPA or serum.
HEK293A cells were pretreated with 1 mg/ml LatB
for 30 min and then stimulated with LPA or serum
for 1 hr.
Data are representative of at least three indepen-
dent experiments. Also see Figure S6.serum concentrations (0.2%) (Figure 6A). The Ki16425-insensi-
tive YAP-dephosphorylating activity in serum could be due to
S1P or other factors.
Both LPA and S1P receptors activate several heterotrimeric G
proteins to initiate intracellular signaling pathways. To determine
whether Ga proteins are involved in YAP regulation, we tested
the effect of Ga overexpression on YAP phosphorylation. Our
data indicate that overexpression of active G12/13 could induce
YAP dephosphorylation (Figure S6D). Indeed, knockdown of
both G12 and G13 largely blocked LPA-induced YAP dephos-
phorylation (Figure 6C), suggesting that G12/13 play a major
role in mediating LPA signaling to the Hippo pathway.
Rho GTPases are known downstream mediators of G12/13
and LPA. We therefore expressed the RhoA-N19 dominant-
negative mutant and found that it blocked serum-induced YAP
dephosphorylation (Figure S6D). Conversely, expression of the
constitutively active RhoA-L63 mutant induced a robust YAP
dephosphorylation even in the absence of serum (Figure S6D).
Likewise, botulinum toxin C3, a specific inhibitor of Rho
GTPases, not only elevated basal phosphorylation of YAP/TAZ,
but also blocked LPA-, S1P-, and serum-induced YAP/TAZ
dephosphorylation (Figure 6D). These data indicate a critical786 Cell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc.role for Rho in mediating the LPA/S1P signal to YAP. We also
found that cotransfection of active G12, G13, and RhoA
repressed Lats2 kinase activity (Figure S6E).Moreover, inhibition
of LPA1 and LPA3 by Ki16425 and inactivation of Rho GTPases
byC3 treatment effectively blocked Lats1 inhibition by LPA, S1P,
and serum (Figures S6F and S6G). Taken together, these data
support a model wherein both LPA and S1P act through
membrane receptors, G12/13, and Rho GTPases to inhibit
Lats1/2 activity and thereby promote YAP activation.
The major function of Rho GTPases is to regulate cellular actin
dynamics. A role of actin cytoskeleton on the Hippo-YAP
pathway has recently been suggested (Dupont et al., 2011; Fer-
na´ndez et al., 2011; Rauskolb et al., 2011; Sansores-Garcia
et al., 2011; Zhao et al., 2012). We therefore determined whether
changes in the actin cytoskeleton contribute to YAP activation
by LPA. YAP nuclear localization under LPA or S1P treatment
correlated with levels of cellular actin filaments (Figures S3B,
S6H, and S6I). When cells were treated with the actin-disrupting
agent latrunculin B (LatB), the effects of LPA or S1P on YAPwere
blocked (Figures 6E and S6I). These results indicate that LPA
or S1P may regulate Lats kinase activity by modulating actin
cytoskeleton dynamics.
Figure 7. Stimulation of Gs-Coupled GPCRs
Increases YAP Phosphorylation
(A) Epinephrine stimulates YAP phosphorylation.
MDA-MB-231 cells were treated with indicated
concentrations of epinephrine for 1 hr. Phosphor-
ylation of CREBwas determined by immunoblotting
with phospho-CREB-specific antibody (pCREB).
(B) Phosphorylation of YAP from the heart of mice
injected with epinephrine is increased. Samples
from three representative pairs (from strong to
weak induction of YAP phosphorylation) of mice
were shown. Epinephrine is known to increase
blood glucose levels, which are indicated under-
neath each sample.
(C) Dopamine agonist dihydrexidine stimulates YAP
phosphorylation. U2OS cells were treated with
10 mM dihydrexidine for 1 hr. YAP phosphorylation
status was assessed.
(D) Glucagon stimulates YAP phosphorylation.
Primarymouse hepatocyteswere treatedwith 2 mM
glucagon for 1 hr, and YAP phosphorylation status
was determined.
(E) Forskolin induces YAP phosphorylation. MDA-
MB-231 cells were treated with different concen-
trations of Forskolin for 1 hr.
(F) Forskolin induces Lats1 phosphorylation.
Endogenous Lats1 was immunoprecipitated from
control cells and Forskolin (Fsk)-treated (10 mM for
1 hr) HEK293A cells, and protein lysates were
divided into two parts, one for IgG IP and the other
for Lats1 IP. Proteins immunoprecipitated were
probed with phosphospecific antibodies against
S909 and T1079 of Lats1.
(G) A proposed model for GPCRs and G proteins in
the regulation of Lats and YAP/TAZ activities. See
Discussion for details.
Data are representative of at least three indepen-
dent experiments. Also see Figure S7 and Tables
S1 and S2.Regulation of YAP Phosphorylation by GPCRs
GPCRs represent one of the largest gene families in the human
genome. There are 1,000 GPCRs that are coupled to 15
different Ga proteins (Wettschureck and Offermanns, 2005).
We asked whether other GPCRs, especially those that are not
coupled to G12/13, could modulate YAP/TAZ activity. It is diffi-
cult to test the effect of many GPCR ligands because the expres-
sion of GPCRs is tissue specific, and only a limited number of
receptors are expressed in any given cell line. However, overex-
pression of GPCRs often can activate signaling, as we observed
by the overexpression of LPA receptors (Figures 6B and S6C).
We therefore tested the effect of representative members of
different GPCR subgroups on YAP/TAZ activity by overexpres-
sion. YAP or TAZ phosphorylation was reduced upon overex-
pression of adrenergic receptor a1B, LPA receptors, purinergic
receptors, 5-hydroxytryptamine receptor 4, muscarinic acetyl-
choline receptor M1, adenosine receptor A1A, angiontensin II
receptor, free fatty acid receptor 1, platelet-activating factor
receptor, thromboxane A2, frizzled homolog D4, complement
component 3a receptor 1, estrogen receptor 1, glutamate
receptor metabotropic 2, opioid receptor D1, secretin receptor,thyroid-stimulating hormone receptor, gastrin-releasing peptide
receptor, melanocortin receptor 1, somatostatin receptor 1,
prostaglandin E receptor 2, and bombesin-like receptor 3 (Table
S1). In contrast, YAP/TAZ phosphorylation was increased by
adrenergic receptor b2, dopamine receptor D1, and glucagon
receptor (Table S1). Our data indicate that GPCRs that activate
G12/13, Gq/11, or Gi/o could repress YAP/TAZ phosphorylation.
On the other hand, GPCRs that mainly activate Gs signaling
could induce YAP/TAZ phosphorylation.
Overexpression of GPCRs could result in nonspecific activa-
tion of Ga that might not occur under physiological conditions.
To further establish the role of specific GPCRs in YAP regulation,
we tested the effect of physiological hormones or GPCR
agonists on YAP/TAZ phosphorylation using cell lines that are
known to express their corresponding receptors. We were
particularly interested in agonists that stimulate Gs-coupled
receptors, as overexpression of Gs-coupled receptors induced
YAP phosphorylation, and their agonists may represent negative
regulators for YAP/TAZ function. In MDA-MB-231 breast cancer
cells, stimulation with epinephrine resulted in a dose-dependent
phosphorylation of YAP (Figure 7A). As expected, epinephrineCell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc. 787
increased phosphorylation of the cAMP-responsive element-
binding protein (CREB), indicating that Gs and cAMP production
are stimulated by epinephrine. In addition, when fed mice were
injected with epinephrine, YAP phosphorylation was significantly
increased in the heart, a physiological target organ of epineph-
rine (Figure 7B), suggesting a role of epinephrine in YAP regula-
tion in vivo.
Overexpression of the dopamine receptor 1 or the glucagon
receptor known to activate Gs also increased YAP phosphoryla-
tion (Table S1). To extend the notion that activation of Gs by
other GPCR agonists also increases YAP phosphorylation, we
examined the effect of dihydrexidine, an agonist for dopamine
receptor 1 and 5. Dihydrexidine treatment strongly increased
YAP phosphorylation in U2OS cells (Figure 7C). As the glucagon
receptor is expressed in hepatocytes, we therefore isolated
primary mouse hepatocytes and tested the effect of glucagon.
As shown in Figure 7D, glucagon treatment also increased
YAP phosphorylation. The above data support that activation
of Gs-coupled receptors results in YAP hyperphosphorylation
and inactivation under physiological conditions.
To further explore the role of cAMP signaling in the Hippo
pathway, we treated cells with forskolin, an activator of adenylyl
cyclase that results in cAMP production. We found that forskolin
effectively increased YAP phosphorylation (Figure 7E). The
cAMP-signaling cascade can activate protein kinase A (PKA)
or exchange protein activated by cAMP (Epac). We found that
the PKA-selective activator 6-Bnz-cAMP dramatically increased
YAP phosphorylation, whereas the effect of an Epac-selective
activator, 8-CPT-20-O-Me-cAMP, on YAP phosphorylation was
less dramatic (Figure S7B). Thus, Gs-coupled GPCR can induce
YAP phosphorylation mainly via cAMP and PKA.
Consistent with the increase in YAPphosphorylation, immuno-
fluorescence staining demonstrated that epinephrine and
forskolin induced an accumulation of cytoplasmic YAP (Fig-
ure S7C). We hypothesized that Gs-coupled signals might
compete with G12/13- and Gq/11-coupled signals. Indeed,
epinephrine and LPA antagonized each other’s effect on YAP
phosphorylation (Figure S7D). Consistent with the pathways
elucidated above, forskolin increased Lats1, but not MST2,
phosphorylation (Figures 7F and S7E). Moreover, epinephrine
increased Lats1 activity (Figure S7F). Our data suggest that
Gs-initiated signaling stimulates Lats kinase activity, therefore
increasing YAP/TAZ phosphorylation.
Differential Functions of Ga in the Regulation of YAP
Phosphorylation
Finally, we tested all Ga subunits for their ability to modulate YAP
phosphorylation by overexpression (Table S2). Because only the
GTP-bound Ga is active and directly participates in signaling, we
expressed constitutively active mutants (GTP-bound form) of Ga
subunits. We found that active Ga mutants decreased YAP
phosphorylation to varying degrees, with the exception of Gs
and Gz. Among the Ga subunits that decreased YAP phosphor-
ylation, G12, G13, Gq, G11, G14, and G15 were more potent
than Gi, Gt, and Go in repressing YAP phosphorylation. More-
over, expression of wild-type G12 or G13, but not wild-type
G11 or Gq, was sufficient to inhibit YAP phosphorylation. These
results indicate that G12/13 is the most potent inhibitor of the788 Cell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc.Hippo pathway, followed by Gq, G11, G14, and G15 (these
four belong to Gq/11 subfamily), whereas Gi, Gt, and Go (all
belong to Gi/o subfamily) are less potent. In contrast, expression
of the constitutively active Gs mutant increased YAP phosphor-
ylation. Together, these data further support differential roles of
various Ga—hence, GPCRs and their corresponding ligands in
regulation of the Hippo-YAP pathway (Figure 7G).
DISCUSSION
In this report, we demonstrate that serum contains an activity that
inhibitsYAP/TAZphosphorylationand increasesYAP/TAZactivity.
Based on biochemical characterizations, we identified LPA and
S1P as potent serum-borne signals regulating the Hippo-YAP
pathway. In addition, we have discovered that epinephrine,
glucagon, and dihydrexidine can stimulate YAP phosphorylation.
Therefore, the Hippo-YAP pathway can be both positively and
negatively regulated by diverse extracellular signals.
Hippo Pathway as a Downstream Branch of GPCR
Signaling
All signals that modulate the Hippo-YAP pathway identified in
this study turn out to be agonists for GPCRs. GPCRs regulate
a wide array of physiological functions and represent the major
targets for therapeutic drugs. Our study places the Hippo-YAP
pathway as a downstream branch of GPCR signaling. We
propose that Lats1/2 kinases are inhibited by G12/13-, Gq/11-,
and Gi/o-coupled receptors and are activated by Gs-coupled
receptors. Moreover, Rho GTPases and actin cytoskeleton
organization appear to be located between Ga and Lats1/2
(Figure 7G). The precise mechanism by which Rho or actin cyto-
skeleton controls Lats1/2 phosphorylation and activity requires
further investigation.
YAP and TAZ are transcription coactivators, and their
activation/inhibition may therefore play an important role in
GPCR-mediated gene regulation. Consistent with this model,
YAP/TAZ is required for the expression of some LPA-induced
genes, indicating a direct role of YAP/TAZ in the transcriptional
response of GPCR. YAP/TAZ play critical roles in cell prolifera-
tion and cell migration in response to LPA. Although the effects
of GPCR agonists on YAP/TAZ phosphorylation are transient
(Figures 1A, S3A, and S3B), the transient dephosphorylation
and nuclear localization effects are sufficient to induce gene
expression (Figure 4A), which may generate long-term physio-
logical effects, such as cell migration and proliferation (Figures
4B and 4C). GPCR activation has been linked to cell proliferation,
and many mechanisms have been proposed (Dorsam and
Gutkind, 2007). Gq/11-, G12/13-, and Gi/o-coupled receptors
usually show stimulatory effects on cell proliferation. This is
consistent with their function on YAP/TAZ activation. The role
of Gs-coupled receptors in cell proliferation is rather complex,
although activation of Gs and PKA is generally associated with
growth inhibition (Stork and Schmitt, 2002). Inhibition of YAP/
TAZ activity by Gs-coupled receptor signaling may lead to
growth inhibition in some types of cells. We noticed that basal
YAP/TAZ activity varies significantly across different cell lines
(F.-X.Y. and K.-L.G., unpublished data), and thus YAP/TAZ
may not respond to Gs-coupled signaling when basal activity
is low (highly phosphorylated), and an alternative signaling may
promote cell proliferation.
Complexity of Hippo-YAP Regulation
The regulation of the Hippo-YAP pathway by multiple signals is
not surprising, given the important role of this pathway in cell
proliferation and apoptosis—hence, organ size control and
tumorigenesis. Multiple regulators may coordinate with each
other to fine-tune physiological and pathological processes.
This scenario is similar to MAP kinases or PI3 kinases, which
are regulated by large numbers of growth factors via receptor
tyrosine kinases (RTK) and other receptors. It is worth noting
that YAP phosphorylation is not affected by the RTK ligands
tested (Figure S1).
Our results suggest that the upstream signals for the Hippo-
YAP pathway are highly redundant (Figure 7G). GPCRs repre-
sent the largest class of cell surface receptors and can couple
to different G proteins (Figure 7G and Table S1). It is likely that
many ligands acting through these G proteins will similarly
modulate Lats1/2 kinases and YAP/TAZ activity.
Regulation of Hippo-YAP by GPCR can be rather complex due
to the presence of multiple receptors for a single agonist. For
example, LPA has at least six receptors, which can be coupled
to different G proteins. Therefore, it is possible that one ligand
may increase YAP phosphorylation in one cell type but decrease
YAP phosphorylation in another cell type depending on which
receptor is dominantly expressed and which Ga is coupled to
the receptor in that particular cell type. We reason that the high
redundancy and complexity may hinder genetic efforts to isolate
upstream signals and receptors for the Hippo-YAP pathway
because knockout or knockdown of a single GPCR may not
significantly affect the Hippo-YAP pathway.
Implication of GPCR-YAP Signaling in Organ Size
and Cancer
Organ size control is a fundamental issue in biology, and final
organ size is determined both intrinsically and extrinsically. The
identification of GPCR ligands as Hippo pathway regulators
opens new possibilities to explore the role of the Hippo pathway
in organ size control. It is possible that certain GPCR-activating
hormones play central roles in organ size control through the
Hippo pathway. Depending on the distribution of ligands and
receptors, the signaling fromGPCR to Hippo pathwaymay regu-
late organ size in a tissue-specific manner. Indeed, it has been
shown that knockout of gprc6a in Leydig cells reduces testis
size (Oury et al., 2011). Gprc6a is able to activate Gq (Kuang
et al., 2005; Wellendorph et al., 2005), and it is possible that
YAP/TAZ activity is compromised in gprc6a knockout cells and
contributes to the small organ size phenotype. The Hippo-YAP
pathway also plays an important function in the nervous system
(Cao et al., 2008). The effect of a dopamine receptor agonist
on YAP activity demonstrated in this study also indicates that
the Hippo-YAP pathway could be dynamically regulated by
neurotransmitters. Therefore, it is also possible that a neuroen-
docrinemechanism is involved in organ size control. Conversely,
YAP may play a critical role in the nervous system and neuronal
activity. Future studies are needed to address these important
biological issues.Elevated YAP/TAZ nuclear localization is observed in many
types of human cancers (Chan et al., 2008; Overholtzer et al.,
2006; Steinhardt et al., 2008; Zender et al., 2006; Zhao et al.,
2007), but the mechanism behind YAP/TAZ activation in cancer
is largely unknown. The connection between GPCR and the
Hippo pathway revealed by this study may provide an explana-
tion for YAP/TAZ activation in certain tumors. GPCR signaling
plays important roles in cancer development as both familial
and somatic activating mutations of GPCRs have been linked
to human cancer (Dorsam and Gutkind, 2007). Recently, GPCR
mutations have been identified in a wide range of human cancer
specimens (Kan et al., 2010; Prickett et al., 2011). We have
demonstrated here that transgenic expression of LPA receptors
increases YAP/TAZ activity and that the oncogenic activity of
YAP/TAZ may contribute to the hyperplasia and tumor pheno-
type in these mice. Mutations of G proteins are also linked to
cancer. For instance, activating mutations of Gq and G11 are
frequently associated with uveal melanoma, the most common
tumor in the eye (Van Raamsdonk et al., 2010). In fact, 83%
of uveal melanoma have activating mutations in either Gq or
G11 in a mutually exclusive manner. Based on our study, one
may predict that constitutive activation of Gq or G11 in uveal
melanomas results in abnormal YAP activation, which then
contributes to uveal melanoma development. Future investiga-
tion to determine the function of YAP/TAZ activation in the devel-
opment of uveal melanoma or other GPCR mutation-containing
cancers may provide new insights into the mechanism of tumor-
igenesis and possibly new therapeutic targets. We hypothesize
that inhibition of YAP/TAZ will be a new approach to treat human
cancers caused by dysregulated Rho GTPase, G-proteins,
GPCRs or their agonists.
EXPERIMENTAL PROCEDURES
Cell Culture
All cell lines were maintained at 37C with 5% CO2. Detailed medium compo-
sition is shown in Supplemental Information. For serum starvation, cells were
incubated in DMEM or DMEM/F12 without other supplements. Detailed
culture conditions are described in Extended Experimental Procedures.
Transfection
Cells were transfected with plasmid DNA using PolyJet DNA In Vitro Tranfec-
tion Reagent (Signagen Laboratories) according to manufacturer’s instruc-
tions. siRNAs were delivered into cells using RNAiMAX (Invitrogen) according
to manufacturer’s instructions. Sources of plasmids used are described in
Extended Experimental Procedures.
Immunoprecipitation and Immunoblotting
Cells were lysed usingmild lysis buffer. Cell lysates were centrifuged for 10min
at 4C, and supernatants were used for immunoprecipitation. Immunoprecip-
itates were washed four times with lysis buffer, and proteins were eluted with
SDS-PAGE sample buffer. Immunoblotting was performed using standard
protocol. Information for antibodies and phos-tag-containing gels is shown
in Extended Experimental Procedures.
Immunofluorescence Staining
HEK293A or MCF10A cells were fixed with 4% paraformaldehyde-PBS for
15 min. Following permeabilization and blocking, cells were incubated with
primary antibodies overnight at 4C. Secondary antibodies used were Alexa
Fluor 488 or 555 (Invitrogen, 1:1,000 dilution). Samples were mounted using
ProLongGoldantifade reagentwithDAPI (Invitrogen), and immunofluorescence
was detected using Olympus confocal microscopy. For paraffin-embeddedCell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc. 789
tissues from control or LPAR transgenic mammary glands or tumors, sections
were prepared and subjected for immunostaining following deparaffinization,
hydration, and antigen retrieval. Detailed methods are described in Extended
Experimental Procedures.
Kinase Assay
Immunoprecipitated MST1 was subjected to a kinase assay in the presence of
500 mM cold ATP, 10 mCi [g-32P]ATP, and 1 mg of GST-Mob. The reaction
mixtures were incubated for 30 min at 30C, terminated with SDS sample
buffer, and subjected to SDS-PAGE and autoradiography. Lats1 or HA-
Lats2 kinase assays were performed similarly but using GST-YAP as
substrates in the absence of [g-32P]ATP. The phosphorylation of GST-YAP
at S127 was determined by immunoblotting using pYAP antibody. Detailed
methods are described in Extended Experimental Procedures.
RNA Extraction, Reverse Transcription, and Real-Time PCR
RNA samples were prepared using RNeasy Plus mini kit (QIAGEN). Reverse
transcription was performed using iScript reverse transcriptase (Bio-Rad).
Real-time PCR was performed using KAPA SYBR FAST qPCR master mix
(Kapa Biosystems). Detailed methods and information for primers are
described in Extended Experimental Procedures.
RNA Interference
Lentiviral shRNAs were obtained from Sigma Aldrich. ShRNA plasmids
together with pMD2.G and psPAX2 were used to produce virus in 293T cells.
ON-TARGET plus SMARTpool siRNAwere purchased from Dharmacon. Infor-
mation for shRNAs is described in Extended Experimental Procedures.
Cell Proliferation Assay
HEK293A cells (expressing control shRNA or YAP/TAZ shRNA, 2 3 105) in
serum-free media were maintained in the presence or absence of 10 mM
LPA for 1, 2, or 3 day. Cell numbers were determined daily using a cell counter
(Bio-Rad). LPA was replenished every day.
Cell Migration Assay
Cell migration assay was performed using BD Falcon Cell culture inserts for
24-well plates with 8.0 mm pore filter according to manufacturer’s instructions.
Detailed methods are described in the Extended Experimental Procedures.
Epinephrine Injection
A detailed protocol for epinephrine injection experiments is shown in the
Extended Experimental Procedures.
Lipid Extraction
A detailed protocol for lipid extraction from serum is shown in the Extended
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2012.06.037.
ACKNOWLEDGMENTS
We thank Drs. Jack Dixon, Edward Dennis, Joan Heller Brown, and Jerold
Chun for constructive comments; Dr. Rick Neubig for several G protein
constructs; Drs. Ji Zhang, Richard Rivera, Zhongrui Zhou, Sunny Xiang,
Andrew Markley, Dong Zhang, and Richard Harkewicz for technical help;
and Jean Guan and Drs. Yanhui Xu and Ryan Russell for critical reading of
the manuscript. This work was supported by grants from NIH and CIRM to
K.-L.G. and GM052872 to X.-D.F. and a grant from Breast Cancer Research
Foundation to G.B.M. J.L.J. was supported by the National Cancer Institute
Training Grant T32CA121938. The cost of confocal imaging was partially
supported by NIH Grant P30 CA23100.790 Cell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc.Received: January 30, 2012
Revised: May 13, 2012
Accepted: June 8, 2012
Published online: August 2, 2012
REFERENCES
Benhamouche, S., Curto, M., Saotome, I., Gladden, A.B., Liu, C.H., Giovan-
nini, M., and McClatchey, A.I. (2010). Nf2/Merlin controls progenitor homeo-
stasis and tumorigenesis in the liver. Genes Dev. 24, 1718–1730.
Cai, J., Zhang, N., Zheng, Y., deWilde, R.F., Maitra, A., and Pan, D. (2010). The
Hippo signaling pathway restricts the oncogenic potential of an intestinal
regeneration program. Genes Dev. 24, 2383–2388.
Camargo, F.D., Gokhale, S., Johnnidis, J.B., Fu, D., Bell, G.W., Jaenisch, R.,
and Brummelkamp, T.R. (2007). YAP1 increases organ size and expands
undifferentiated progenitor cells. Curr. Biol. 17, 2054–2060.
Cao, X., Pfaff, S.L., and Gage, F.H. (2008). YAP regulates neural progenitor cell
number via the TEA domain transcription factor. Genes Dev. 22, 3320–3334.
Chan, S.W., Lim, C.J., Guo, K., Ng, C.P., Lee, I., Hunziker, W., Zeng, Q., and
Hong, W. (2008). A role for TAZ in migration, invasion, and tumorigenesis of
breast cancer cells. Cancer Res. 68, 2592–2598.
Choi, J.W., Herr, D.R., Noguchi, K., Yung, Y.C., Lee, C.W., Mutoh, T., Lin, M.E.,
Teo, S.T., Park, K.E., Mosley, A.N., and Chun, J. (2010). LPA receptors:
subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 50, 157–186.
Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S.A.,
Gayyed, M.F., Anders, R.A., Maitra, A., and Pan, D. (2007). Elucidation of
a universal size-control mechanism in Drosophila and mammals. Cell 130,
1120–1133.
Dorsam, R.T., and Gutkind, J.S. (2007). G-protein-coupled receptors and
cancer. Nat. Rev. Cancer 7, 79–94.
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M.,
Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011). Role of
YAP/TAZ in mechanotransduction. Nature 474, 179–183.
Ferna´ndez, B.G., Gaspar, P., Bra´s-Pereira, C., Jezowska, B., Rebelo, S.R.,
and Janody, F. (2011). Actin-Capping Protein and the Hippo pathway regulate
F-actin and tissue growth in Drosophila. Development 138, 2337–2346.
Hao, Y., Chun, A., Cheung, K., Rashidi, B., and Yang, X. (2008). Tumor
suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem.
283, 5496–5509.
Kan, Z., Jaiswal, B.S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H.M., Yue,
P., Haverty, P.M., Bourgon, R., Zheng, J., et al. (2010). Diverse somatic muta-
tion patterns and pathway alterations in human cancers. Nature 466, 869–873.
Kuang, D., Yao, Y., Lam, J., Tsushima, R.G., and Hampson, D.R. (2005).
Cloning and characterization of a family C orphan G-protein coupled receptor.
J. Neurochem. 93, 383–391.
Lee, C.H., Inoki, K., and Guan, K.L. (2007). mTOR pathway as a target in tissue
hypertrophy. Annu. Rev. Pharmacol. Toxicol. 47, 443–467.
Lee, K.P., Lee, J.H., Kim, T.S., Kim, T.H., Park, H.D., Byun, J.S., Kim, M.C.,
Jeong, W.I., Calvisi, D.F., Kim, J.M., and Lim, D.S. (2010). The Hippo-Salvador
pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigen-
esis. Proc. Natl. Acad. Sci. USA 107, 8248–8253.
Lei, Q.Y., Zhang, H., Zhao, B., Zha, Z.Y., Bai, F., Pei, X.H., Zhao, S., Xiong, Y.,
and Guan, K.L. (2008). TAZ promotes cell proliferation and epithelial-mesen-
chymal transition and is inhibited by the hippo pathway. Mol. Cell. Biol. 28,
2426–2436.
Li, L., Yun, S.H., Keblesh, J., Trommer, B.L., Xiong, H., Radulovic, J., and
Tourtellotte, W.G. (2007). Egr3, a synaptic activity regulated transcription
factor that is essential for learning andmemory. Mol. Cell. Neurosci. 35, 76–88.
Liu, S., Umezu-Goto, M., Murph, M., Lu, Y., Liu, W., Zhang, F., Yu, S.,
Stephens, L.C., Cui, X., Murrow, G., et al. (2009). Expression of autotaxin
and lysophosphatidic acid receptors increases mammary tumorigenesis,
invasion, and metastases. Cancer Cell 15, 539–550.
Liu, C.Y., Zha, Z.Y., Zhou, X., Zhang, H., Huang, W., Zhao, D., Li, T., Chan,
S.W., Lim, C.J., Hong, W., et al. (2010). The hippo tumor pathway promotes
TAZ degradation by phosphorylating a phosphodegron and recruiting the
SCFbeta-TrCP E3 ligase. J. Biol. Chem. 285, 37159–37169.
Lu, L., Li, Y., Kim, S.M., Bossuyt, W., Liu, P., Qiu, Q., Wang, Y., Halder, G.,
Finegold, M.J., Lee, J.S., and Johnson, R.L. (2010). Hippo signaling is a potent
in vivo growth and tumor suppressor pathway in the mammalian liver. Proc.
Natl. Acad. Sci. USA 107, 1437–1442.
Ludwig, A., Uvarov, P., Soni, S., Thomas-Crusells, J., Airaksinen, M.S., and
Rivera, C. (2011). Early growth response 4 mediates BDNF induction of
potassium chloride cotransporter 2 transcription. J. Neurosci. 31, 644–649.
Ohta, H., Sato, K., Murata, N., Damirin, A., Malchinkhuu, E., Kon, J., Kimura, T.,
Tobo, M., Yamazaki, Y., Watanabe, T., et al. (2003). Ki16425, a subtype-selec-
tive antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharma-
col. 64, 994–1005.
Oury, F., Sumara, G., Sumara, O., Ferron, M., Chang, H., Smith, C.E., Hermo,
L., Suarez, S., Roth, B.L., Ducy, P., and Karsenty, G. (2011). Endocrine
regulation of male fertility by the skeleton. Cell 144, 796–809.
Overholtzer, M., Zhang, J., Smolen, G.A., Muir, B., Li, W., Sgroi, D.C., Deng,
C.X., Brugge, J.S., and Haber, D.A. (2006). Transforming properties of YAP,
a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl.
Acad. Sci. USA 103, 12405–12410.
Pan, D. (2007). Hippo signaling in organ size control. Genes Dev. 21, 886–897.
Prickett, T.D., Wei, X., Cardenas-Navia, I., Teer, J.K., Lin, J.C., Walia, V.,
Gartner, J., Jiang, J., Cherukuri, P.F., Molinolo, A., et al. (2011). Exon capture
analysis of G protein-coupled receptors identifies activating mutations in
GRM3 in melanoma. Nat. Genet. 43, 1119–1126.
Quehenberger, O., Armando, A.M., Brown, A.H., Milne, S.B., Myers, D.S.,
Merrill, A.H., Bandyopadhyay, S., Jones, K.N., Kelly, S., Shaner, R.L., et al.
(2010). Lipidomics reveals a remarkable diversity of lipids in human plasma.
J. Lipid Res. 51, 3299–3305.
Rauskolb, C., Pan, G., Reddy, B.V., Oh, H., and Irvine, K.D. (2011). Zyxin links
fat signaling to the hippo pathway. PLoS Biol. 9, e1000624.
Rosen, H., Gonzalez-Cabrera, P.J., Sanna, M.G., and Brown, S. (2009).
Sphingosine 1-phosphate receptor signaling. Annu. Rev. Biochem. 78,
743–768.
Sansores-Garcia, L., Bossuyt, W., Wada, K., Yonemura, S., Tao, C., Sasaki,
H., and Halder, G. (2011). Modulating F-actin organization induces organ
growth by affecting the Hippo pathway. EMBO J. 30, 2325–2335.
Shida, D., Kitayama, J., Yamaguchi, H., Okaji, Y., Tsuno, N.H., Watanabe, T.,
Takuwa, Y., and Nagawa, H. (2003). Lysophosphatidic acid (LPA) enhances
the metastatic potential of human colon carcinoma DLD1 cells through
LPA1. Cancer Res. 63, 1706–1711.
Steinhardt, A.A., Gayyed, M.F., Klein, A.P., Dong, J., Maitra, A., Pan, D.,
Montgomery, E.A., and Anders, R.A. (2008). Expression of Yes-associated
protein in common solid tumors. Hum. Pathol. 39, 1582–1589.
Stork, P.J., and Schmitt, J.M. (2002). Crosstalk between cAMP and MAP
kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12,
258–266.van Corven, E.J., Groenink, A., Jalink, K., Eichholtz, T., and Moolenaar, W.H.
(1989). Lysophosphatidate-induced cell proliferation: identification and
dissection of signaling pathways mediated by G proteins. Cell 59, 45–54.
Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B., Garrido, M.C., Vemula,
S., Wiesner, T., Obenauf, A.C., Wackernagel, W., Green, G., Bouvier, N., et al.
(2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191–
2199.
Wellendorph, P., Hansen, K.B., Balsgaard, A., Greenwood, J.R., Egebjerg, J.,
and Bra¨uner-Osborne, H. (2005). Deorphanization of GPRC6A: a promiscuous
L-alpha-amino acid receptor with preference for basic amino acids. Mol. Phar-
macol. 67, 589–597.
Wettschureck, N., and Offermanns, S. (2005). Mammalian G proteins and their
cell type specific functions. Physiol. Rev. 85, 1159–1204.
Xu, M.Z., Yao, T.J., Lee, N.P., Ng, I.O., Chan, Y.T., Zender, L., Lowe, S.W.,
Poon, R.T., and Luk, J.M. (2009). Yes-associated protein is an independent
prognostic marker in hepatocellular carcinoma. Cancer 115, 4576–4585.
Xu, Y., Stamenkovic, I., and Yu, Q. (2010). CD44 attenuates activation of the
hippo signaling pathway and is a prime therapeutic target for glioblastoma.
Cancer Res. 70, 2455–2464.
Zender, L., Spector, M.S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J.,
Fan, S.T., Luk, J.M., Wigler, M., Hannon, G.J., et al. (2006). Identification and
validation of oncogenes in liver cancer using an integrative oncogenomic
approach. Cell 125, 1253–1267.
Zhang, N., Bai, H., David, K.K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu,
P., Anders, R.A., and Pan, D. (2010). The Merlin/NF2 tumor suppressor
functions through the YAP oncoprotein to regulate tissue homeostasis in
mammals. Dev. Cell 19, 27–38.
Zhao, B., Wei, X., Li, W., Udan, R.S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu,
J., Li, L., et al. (2007). Inactivation of YAP oncoprotein by the Hippo pathway is
involved in cell contact inhibition and tissue growth control. Genes Dev. 21,
2747–2761.
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J.D., Wang, C.Y.,
Chinnaiyan, A.M., et al. (2008). TEADmediates YAP-dependent gene induction
and growth control. Genes Dev. 22, 1962–1971.
Zhao, B., Li, L., Lei, Q., and Guan, K.L. (2010a). The Hippo-YAP pathway in
organ size control and tumorigenesis: an updated version. Genes Dev. 24,
862–874.
Zhao, B., Li, L., Tumaneng, K., Wang, C.Y., and Guan, K.L. (2010b).
A coordinated phosphorylation by Lats and CK1 regulates YAP stability
through SCF(beta-TRCP). Genes Dev. 24, 72–85.
Zhao, B., Li, L., Wang, L., Wang, C.Y., Yu, J., and Guan, K.L. (2012). Cell
detachment activates the Hippo pathway via cytoskeleton reorganization to
induce anoikis. Genes Dev. 26, 54–68.
Zhou, D., Conrad, C., Xia, F., Park, J.S., Payer, B., Yin, Y., Lauwers, G.Y.,
Thasler, W., Lee, J.T., Avruch, J., and Bardeesy, N. (2009). Mst1 and Mst2
maintain hepatocyte quiescence and suppress hepatocellular carcinoma
development through inactivation of the Yap1 oncogene. Cancer Cell 16,
425–438.Cell 150, 780–791, August 17, 2012 ª2012 Elsevier Inc. 791
